Intracoronary Analysis of Cardiac Allograft Vasculopathy by Means of Optical Coherence Tomography (OCTandCAV)
Intimal Proliferation, Immunosuppression
About this trial
This is an interventional treatment trial for Intimal Proliferation focused on measuring intima, thickness, transplantation, cardiology, immunosuppression
Eligibility Criteria
Inclusion Criteria:
- Patients with heart transplantation
- Patient with coronary artery disease
- Age between 18 and 80 years
Exclusion Criteria:
- Renal insufficiency (> 265 µmol/l)
- Incapability to give informed consent
- Cardiogenic shock of patient with KILLIP III or IV
- pregnant or breast feeding females
- insufficient contraception (only for substudy 3)
Sites / Locations
- University Hospital Zurich, Division of CardiologyRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Everolimus (Certican®)
Mycophenolate mofetil (CellCept®)
Electronic (computer-assisted) randomization of an immunosuppressive protocol WITH Everolimus (Certican®). No protocol with Mycophenolate mofetil (CellCept®). Daily dosage administered depending on blood concentration (control interval 6-12 months)
Electronic (computer-assisted) randomization of an immunosuppressive protocol WITHOUT Everolimus (Certican®), instead administration of Mycophenolate mofetil (CellCept®). No protocol with Everolimus (Certican®). Daily dosage administered depending on blood concentration (control interval 6-12 months)